



IDFC CORE EQUITY FUND

(Previously known as IDFC Classic Equity Fund w.e.f. May 28, 2018)
Large & Mid Cap Fund - An open ended equity scheme investing in both large cap and mid cap stocks

IDFC Core Equity Fund is a diversified equity fund with a large & mid cap bias currently. The focus of the fund is to build a portfolio of Quality companies while being cognizant of the relative valuation.

FUND PHILOSOPHY*

The fund builds a portfolio of quality stocks with lower relative valuations. Quality (for non-financial stocks) is ascribed on three fronts - conversion of EBIDTA to operating cash - OCF as % of EBIDTA > 33%; Moderate leverage: Debt/EBIDTA < 3x; Profitability: EBIDTA / Net operating Assets > 30%. Companies that qualify on these three parameters and those which are relatively cheaper within a peer group on P/B basis form part of the 'quality' universe. Roughly 50% of the portfolio will comprise of such quality companies; ~30% would be for financial sector and balance 20% would be invested in benchmark heavyweights and themes, which we expect to play out over next 6/12 months. On a tactical basis, the fund may take a part of its overall holding through near month stock futures.

OUTLOOK

Domestic markets have been broad-based with broader markets outperforming the Nifty 50, first time after 2 years. Since the bottom in March, the Small Cap Index has moved up significantly higher than the Large and Mid Cap indices.

Going forward, given uncertainty on the duration and severity of the pandemic, economic recovery in FY22 remains uncertain. This is also reflected in the earnings estimates across sectors. The speed of catchup in earnings to FY20 levels will be the key factor that will be tracked by markets. On the other hand, the move from Mar'20 till now has seen a long stretch of the market upmove, with only one correction, which has happened quite early in the bull market. Investors should be ready for a correction and use it to their advantage.

FUND FEATURES: (Data as on 30th September'20)

Category: Large & Mid Cap

Monthly Avg AUM: ₹2,115.56 Crores

Inception Date: 9th August 2005

Fund Manager: Mr. Anoop Bhaskar (w.e.f. 30/04/2016)

Benchmark: LargeMidcap 250 TRI (w.e.f. 7th October 2019)

Minimum Investment Amount: ₹5,000/- and any amount thereafter.

Exit Load:

● If redeemed/switched out within 365 days from the date of allotment:

- ▶ Upto 10% of investment: Nil,
- ▶ For remaining investment: 1% of applicable NAV.

● If redeemed / switched out after 365 days from date of allotment: Nil. (w.e.f. May 08, 2020)

SIP Frequency: Monthly (Investor may choose any day of the month except 29th, 30th and 31st as the date of instalment.)

Options Available: Growth, Dividend - (Payout, Reinvestment and Sweep (from Equity Schemes to Debt Schemes only))

Other Parameters:

Beta: 0.99

R Square: 0.97

Standard Deviation (Annualized): 23.17%

PLAN	DIVIDEND RECORD DATE	₹/UNIT	NAV
REGULAR	16-Mar-20	1.03	12.0100
	14-Mar-19	0.80	15.4200
	12-Mar-18	1.01	16.4254
DIRECT	16-Mar-20	0.39	13.7900
	14-Mar-19	0.90	17.4700
	12-Mar-18	1.13	18.3717

The above mentioned is the current strategy of the Fund Manager. However, asset allocation and investment strategy shall be within broad parameters of Scheme Information Document.

*The benchmark of the fund has been revised from S&P BSE 200 TRI to Nifty LargeMidcap 250 TRI w.e.f. 7th October 2019

Face Value per Unit (in ₹) is 10

Dividend is not guaranteed and past performance may or may not be sustained in future. Pursuant to payment of dividend, the NAV of the scheme would fall to the extent of payout and statutory levy (as applicable).

Ratios calculated on the basis of 3 years history of monthly data.

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

PORTFOLIO


(30 September 2020)



Name of the Instrument	% to NAV	Name of the Instrument	% to NAV
Equity and Equity related Instruments	98.73%	Mas Financial Services	0.69%
Pharmaceuticals	15.87%	ICICI Lombard General Insurance Company	0.61%
IPCA Laboratories	4.14%	M&M Financial Services	0.18%
Lupin	2.40%	Petroleum Products	4.37%
Dr. Reddy's Laboratories	2.00%	Reliance Industries	3.12%
Cadila Healthcare	1.79%	Bharat Petroleum Corporation	1.26%
Sun Pharmaceutical Industries	1.67%	Auto	4.08%
Alkem Laboratories	1.43%	Mahindra & Mahindra	1.49%
Aurobindo Pharma	1.13%	Bajaj Auto	1.31%
Alembic Pharmaceuticals	0.72%	Hero MotoCorp	1.28%
Indoco Remedies	0.58%	Consumer Non Durables	3.87%
Banks	14.53%	Emami	0.90%
HDFC Bank	4.99%	Hindustan Unilever	0.90%
ICICI Bank	4.31%	ITC	0.84%
Axis Bank	1.73%	Tata Consumer Products	0.74%
Kotak Mahindra Bank	1.46%	Marico	0.48%
State Bank of India	1.30%	Power	3.26%
RBL Bank	0.73%	Torrent Power	1.81%
Software	12.94%	Kalpataru Power Transmission	0.86%
Infosys	6.21%	Nava Bharat Ventures	0.58%
Birlasoft	2.07%	Chemicals	2.63%
Mastek	1.56%	Deepak Nitrite	2.63%
Tech Mahindra	1.25%	Consumer Durables	2.59%
Mphasis	1.18%	Crompton Greaves Consumer Electricals	1.39%
KPIT Technologies	0.67%	Voltas	1.19%
Auto Ancillaries	6.19%	Construction Project	2.49%
MRF	1.95%	KEC International	1.41%
Apollo Tyres	1.32%	Larsen & Toubro	1.07%
Exide Industries	1.15%	Gas	2.33%
Balkrishna Industries	0.86%	Mahanagar Gas	1.29%
Minda Industries	0.46%	Gujarat State Petronet	1.04%
Asahi India Glass	0.44%	Telecom - Services	2.26%
Industrial Products	5.90%	Bharti Airtel	2.26%
Supreme Industries	2.13%	Hotels/ Resorts and Other Recreational Activities	1.90%
AIA Engineering	2.11%	The Indian Hotels Company	1.90%
Essel Propack	1.00%	Ferrous Metals	1.50%
Cummins India	0.66%	Jindal Steel & Power	1.50%
Cement	5.55%	Retailing	1.26%
ACC	2.19%	Aditya Birla Fashion and Retail	1.26%
The Ramco Cements	1.80%	Preference Shares	0.005%
Ambuja Cements	1.55%	Media & Entertainment	0.005%
Finance	5.22%	Zee Entertainment Enterprises	0.005%
ICICI Securities	2.50%	Net Cash and Cash Equivalent	1.26%
Sundaram Finance	1.24%	Grand Total	100.00%



SECTOR ALLOCATION



This product is suitable for investors who are seeking*:

- To create wealth over long term
- Investment predominantly in equity and equity related instruments in large and mid-cap companies

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.